Morphomics predicts response to ipilimumab in patients with stage IV melanoma. Issue 4 (7th August 2015)
- Record Type:
- Journal Article
- Title:
- Morphomics predicts response to ipilimumab in patients with stage IV melanoma. Issue 4 (7th August 2015)
- Main Title:
- Morphomics predicts response to ipilimumab in patients with stage IV melanoma
- Authors:
- Sabel, Michael S.
Lee, Jay
Wang, Anran
Lao, Christopher
Holcombe, Sven
Wang, Stewart - Abstract:
- <abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jso24003-sec-0001" sec-type="section"> <title>Introduction</title> <p>Factors predictive of response to immunotherapy are needed to select appropriate patients. As morphometric analysis can be an objective surrogate for underlying physiology, we explored the possibility that morphomics may predict response among stage IV melanoma patients treated with ipilimumab.</p> </sec> <sec id="jso24003-sec-0002" sec-type="section"> <title>Methods</title> <p>We identified stage IV melanoma patients treated with ipilimumab who had an appropriate CT scan within a 6 month window. Using semi‐automated algorithms, we acquired several morphomic measurements. Toxicity and response rate compared by quartile using Fisher's exact test or chi‐square, while survival after initiation of ipilimumab was compared by quartile using the log‐rank test.</p> </sec> <sec id="jso24003-sec-0003" sec-type="section"> <title>Results</title> <p>While there was a significant correlation between toxicity and response (<italic>P</italic> &lt; .003), morphomics failed to predict either severity of toxicity or specific side effects. Psoas density was significantly associated with response rate, both excluding stable disease (36.4% vs 9.1%, <italic>P</italic> = .054), and including stable disease (54.5% versus 18.2%, <italic>P</italic> = 0.045). Survival after initiation of ipilimumab was significantly associated<abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jso24003-sec-0001" sec-type="section"> <title>Introduction</title> <p>Factors predictive of response to immunotherapy are needed to select appropriate patients. As morphometric analysis can be an objective surrogate for underlying physiology, we explored the possibility that morphomics may predict response among stage IV melanoma patients treated with ipilimumab.</p> </sec> <sec id="jso24003-sec-0002" sec-type="section"> <title>Methods</title> <p>We identified stage IV melanoma patients treated with ipilimumab who had an appropriate CT scan within a 6 month window. Using semi‐automated algorithms, we acquired several morphomic measurements. Toxicity and response rate compared by quartile using Fisher's exact test or chi‐square, while survival after initiation of ipilimumab was compared by quartile using the log‐rank test.</p> </sec> <sec id="jso24003-sec-0003" sec-type="section"> <title>Results</title> <p>While there was a significant correlation between toxicity and response (<italic>P</italic> &lt; .003), morphomics failed to predict either severity of toxicity or specific side effects. Psoas density was significantly associated with response rate, both excluding stable disease (36.4% vs 9.1%, <italic>P</italic> = .054), and including stable disease (54.5% versus 18.2%, <italic>P</italic> = 0.045). Survival after initiation of ipilimumab was significantly associated with psoas density (<italic>P</italic> = 0.04) and visceral fat distance (<italic>P</italic> = 0.022).</p> </sec> <sec id="jso24003-sec-0004" sec-type="section"> <title>Discussion</title> <p>In an exploratory study of patients with metastatic melanoma being treated with ipilimumab, psoas density and spine‐fascia distance correlated with response and survival. Pre‐treatment morphomic analysis, as a correlate of underlying physiology, may help predict response to immunotherapy. <italic>J. Surg. Oncol. 2015; 112:333–337</italic>. © 2015 Wiley Periodicals, Inc.</p> </sec> </abstract> … (more)
- Is Part Of:
- Journal of surgical oncology. Volume 112:Issue 4(2015:Sep. 15)
- Journal:
- Journal of surgical oncology
- Issue:
- Volume 112:Issue 4(2015:Sep. 15)
- Issue Display:
- Volume 112, Issue 4 (2015)
- Year:
- 2015
- Volume:
- 112
- Issue:
- 4
- Issue Sort Value:
- 2015-0112-0004-0000
- Page Start:
- 333
- Page End:
- 337
- Publication Date:
- 2015-08-07
- Subjects:
- Cancer -- Surgery -- Periodicals
Neoplasms -- Periodicals
616 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1096-9098 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/jso.24003 ↗
- Languages:
- English
- ISSNs:
- 0022-4790
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5067.380000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 4193.xml